Adaptive radiation dose reduction for HPV-positive oropharyngeal cancer based on mid-treatment tumor response

What this Trial Is About

Researchers are evaluating treatment options for people with HPV-positive oropharyngeal carcinoma, a type of throat cancer. This phase II clinical trial aims to see if reducing the intensity of chemoradiation based on how tumors respond mid-treatment is feasible. The study focuses on progression-free survival at 2 years and also looks at survival, quality of life, and long-term side effects. It includes testing for HPV markers in blood and saliva and uses imaging to predict outcomes. Participants receive radiation therapy combined with chemotherapy drug cisplatinum. Those showing a strong tumor response at 4 weeks may have their radiation dose lowered and duration shortened, with different groups receiving varying treatment lengths and doses based on tumor shrinkage and HPV DNA clearance. Some groups receive standard treatment, while others receive de-escalated radiation schedules to reduce treatment burden. During the study, patients undergo scans and blood tests to monitor tumor response and HPV DNA levels. Quality of life questionnaires and assessments of side effects are completed to understand treatment impact. The main measure is progression-free survival at 2 years, with ongoing follow-up to assess disease control and long-term effects. Participation lasts through treatment and extends to at least 2 years for outcome evaluation.

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma